Disease modifying anti-rheumatic drugs/Definition: Difference between revisions
Jump to navigation
Jump to search
imported>Howard C. Berkowitz (New page: Drugs that directly affect the underlying autoimmune processes in rheumatological disease, rather than act simply as analgesics or nonspecific antiinflammatories; they inc...) |
imported>Howard C. Berkowitz No edit summary |
||
| Line 1: | Line 1: | ||
Drugs that directly affect the underlying autoimmune processes in [[rheumatology|rheumatological disease]], rather than act simply as analgesics or nonspecific antiinflammatories; they include gold compounds (e.g., aurothioglucose), [[antimalarial]]s, [[penicillamine]], and [[monoclonal antibody|monoclonal antibodies]] against [[ | <noinclude>{{subpages}}</noinclude> | ||
Drugs that directly affect the underlying autoimmune processes in [[rheumatology|rheumatological disease]], rather than act simply as analgesics or nonspecific antiinflammatories; they include gold compounds (e.g., aurothioglucose), [[antimalarial]]s, [[penicillamine]], and [[monoclonal antibody|monoclonal antibodies]] against [[tumor necrosis factor-alpha]] and other immunochemicals | |||
Latest revision as of 18:00, 18 September 2010
This article contains just a definition and optionally other subpages (such as a list of related articles), but no metadata. Create the metadata page if you want to expand this into a full article.
Disease modifying anti-rheumatic drugs [r]: Drugs that directly affect the underlying autoimmune processes in rheumatological disease, rather than act simply as analgesics or nonspecific antiinflammatories; they include gold compounds (e.g., aurothioglucose), antimalarials, penicillamine, and monoclonal antibodies against tumor necrosis factor-alpha and other immunochemicals